In re­ver­sal, em­ploy­ers, union groups push for Con­gress to al­low Medicare to ne­go­ti­ate drug prices

The largest US unions, em­ploy­er groups, and more than two dozen oth­er group pur­chasers have long sup­port­ed the push for mar­ket forces like gener­ic drug and biosim­i­lar com­pe­ti­tion to bring down the prices of drugs across the board. But now, those same groups are call­ing on top law­mak­ers on both sides of the aisle to do more and al­low Medicare to ne­go­ti­ate drug prices.

“Ne­go­ti­at­ed prices should con­sid­er key com­po­nents in­clud­ing: re­search and de­vel­op­ment costs, in­clud­ing pri­or fed­er­al sup­port; da­ta on net prices, sales across all mar­kets, and pro­ject­ed rev­enue; costs of pro­duc­tion and dis­tri­b­u­tion; da­ta on com­par­a­tive ef­fec­tive­ness,” the groups said in a let­ter Tues­day to Sens. Chuck Schumer (D-NY), Mitch Mc­Connell (R-KY), and Reps. Nan­cy Pelosi (D-CA) and Kevin Mc­Carthy (R-CA).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.